Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a, Double-Masked, Randomized, Placebo-Controlled, Single-Administration Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects

NCT02965664 is registered in ClinicalTrials.gov with Orasis Pharmaceuticals Ltd. as lead sponsor.

NCT NCT02965664
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02965664 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a, Double-Masked, Randomized, Placebo-Controlled, Single-Administration Study to Establish Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects
Lead sponsor
Orasis Pharmaceuticals Ltd.
Phase
Phase 2
Overall status
Completed
Start date
December 31, 2016
Completion date
April 30, 2017
Enrollment
36 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

presbyopia